« Return to News | Awards & Advancement

PPD Appoints New CEO, Eshelman to Serve as Executive Director of Board

Wednesday, May 20, 2009 07:00 AM

Wilmington, N.C.-based PPD is promoting current CEO Fred Eshelman to the newly created position of executive chairman of the board of directors, effective July 1.

In this role, Eshelman will provide strategic direction to the company and oversee the implementation of the company’s strategic and business plans, including the company’s compound partnering business.

David Grange, a member of PPD’s board since 2003, will replace Eshelman as CEO, reporting to Eshelman. Previously, Grange served as president and CEO of the McCormick Foundation, a nonprofit devoted to advancing “the ideals of a free, democratic society by investing in our children, communities and country,” according to the organization's web site. Before joining the Foundation in 1999, Grange had a 30-year career in the U.S. Army and is a retired brigadier general.

"General Grange brings a great combination of global geographical experience and knowledge, demonstrated leadership from his business and military careers, financial management experience and first-hand knowledge of PPD as a member of our board since 2003," said Eshelman in a company statement.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.